BackgroundAlthough Fingolimod (FGD) and Natalizumab (NTZ) appear to be effective in relapsing-remitting multiple sclerosis (RRMS), they have never been directly compared in a randomized clinical trial
#Age<40 years n (%); NR: Not Reported; RGT: Respond-Guided therapy; AEs: adverse events. *Including HCV-2/3 and HCV-6 groups. Only the data on HCV-6 groups were included in the current meta-analysis.
BackgroundImmune checkpoint inhibitors (ICIs) combined with standard therapy (ST) have emerged as a novel treatment strategy for recurrent or advanced cervical cancer (r/a CC). However, the available
Background: Non-small cell lung cancer (NSCLC) accounts for about 85% of generally reported lung cancer patients. Objectives: This is a systematic review of the clinical efficacy and safety of osimert
